Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk

Journal of Perinatology

Volumn 27, Issue 4, 2007, Pages 241-243

  Russell, M A ^a   Carpenter, M W ^b   Akhtar, M S ^c   Lagattuta, T F ^d   Egorin, M J ^d  

^a VA MEDICAL CENTER   (United States)

^b WOMEN AND INFANTS HOSPITAL   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CGP 74588; DRUG METABOLITE; IMATINIB; UNCLASSIFIED DRUG;

ARTICLE; BLOOD PLACENTA BARRIER; BREAST FEEDING; BREAST MILK; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG MILK LEVEL; DRUG PENETRATION; DRUG SAFETY; DRUG TISSUE LEVEL; FEMALE; HUMAN; LABOR INDUCTION; LEUKOCYTOSIS; MATERNAL BLOOD; NEWBORN; NEWBORN ASSESSMENT; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLACENTA; PLACENTAL TRANSFER; PREGNANCY COMPLICATION; PREGNANT WOMAN; PRENATAL CARE; SPLENOMEGALY; THROMBOCYTOSIS; UMBILICAL CORD BLOOD; VAGINAL DELIVERY;

ANTINEOPLASTIC AGENTS; FEMALE; FETAL BLOOD; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MILK, HUMAN; PIPERAZINES; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PYRIMIDINES;

EID: 33947696695     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/sj.jp.7211665     Document Type: Article

References (19)

1. Copeland LJ, Landon MB. Malignant diseases and pregnancy In Gabbe S, Niebyl J, and Simpson J (eds). Obstetrics: Normal and Problem Pregnancies. Philadelphia (PA): Churchill Livingston, 2002; 1255-1281.
2. Savage DG, Antman KH. Imatinib Mesylate - a new oral targeted therapy. N Engl J Med 2002; 346: 683-693.
3. Investigators Brochure. STI571 (formerly CGP57148B) and data on file, Novartis Pharma AG, Basel, Switzerland.
4. Hensley ML, Ford JM. Imatinib Treatment: Specific Issues Related to Safety, Fertility, and Pregnancy. Seminars in Hematology 2003; 40: 21-25.
5. Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB et al. Pregnancy among patients with cronic myeloid leukemia treated with imatinib. J Clin Oncol 2006; 24: 1204-1208.
6. Heartin E, Walkinshaw S, Clark RE. Successful outcome of pregnancy in chronic myeloid leukemia treated with imatinib. Leukemia Lymphoma 2004; 45: 1307-1308.
7. Alkindi S, Dennison D, Pathare A. Imatinib in pregnancy. Eur J Haematol 2005; 74: 535-537.
8. Ali R, Ozkalemkas F, Ozkocaman V, Ozcelik T, Ozan U, Kimya Y et al. Pregnancy under treatement of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML): Outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res 2005; 29: 971-973.
9. Prabhash F, Sastry PS, Biswas G, Bakshi A, Prasad N, Menon H et al. Pregnancy outcome of two patients with imatinib. Ann Oncol 2005; 16: 1983-1984.
10. Choudhary DR, Mishra P, Kumar R, Mahapatra M, Choudhary VP. Pregnancy on imatinib: Fatal outcome with meningocele. Ann Oncol 2006; 17: 178-179.
11. Parise RA, Ramanathan RF, Hayes MJ, Egorin MJ. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 791: 39-44.
12. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701-4707.
13. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44: 879-894.
14. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935-942.
15. Druker BJ et al. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. NEJM 2001; 344: 1031-1037.
16. Widmer N, Colombo S, Buclin T, Decosterd L. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 2003; 102: 1142.
17. Mathias A, Hitti J, Unadkat J. P-glycoprotein and breast cancer resistance protein in human placentae of various gestational ages. Am J Physiol Regul Integr Comp Physiol 2005; 289: R963-R969.
18. Alvarez R, Kantarjian H, Cortes J. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006; 81: 1241-1257.
19. Nystrom H, Lindblom P, Wickman A, Andersson I et al. Platelet-derived growth factor B retention is essential for development of normal structure and function of conduit vessels and capillaries. Cardiovasc Res 2006; 71: 557-565.